E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Cancer of the adrenal glands |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10001388 |
E.1.2 | Term | Adrenocortical carcinoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to compare the efficacy of mitotane treatment vs. observational follow-up only in prolonging survival without disease recurrence in patients with adrenocortical carcinoma at low-intermediate risk of recurrence after complete surgical resection of the tumour. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are: - Overall survival - Time to Recurrence - Disease Free Survival - Quality of life assessment - Toxicity assessment - Assessment of the impact of mitotane plasma levels and time needed to reach the therapeutic interval on the efficacy of treatment. - Assessment of the efficacy of the mitotane administration in predefined subgroups of patients stratified according to: - type of hormone secretion - stage of disease - histopathologic characteristics |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Histologically confirmed diagnosis of ACC according to Weiss system 2. Low-intermediate risk of relapse defined as: o Stage I-III (according to ENSAT classification 2008) 3. Microscopically complete resection, defined as no evidence of microscopic residual disease based on surgical reports, histopathology and post-operative imaging. Detailed pathological and surgical reports prepared according to guidelines should be available for assessment. 4. Ki 67 </= 10% 5. Post-operative imaging (CT with contrast medium of chest, abdomen and pelvis (or alternatively MRI) demonstrating no evidence of disease within 4 weeks before randomisation 6. Age >/= 18 years 7. ECOG performance status 0-2 8. Adequate bone marrow reserve (neutrophils >/=1000/mm3 and/or platelets >/= 80000/ mm3) 9. Ability to comply with the protocol procedures 10. Written informed consent |
|
E.4 | Principal exclusion criteria |
1. Time between primary surgery and randomisation > 3 months. 2. Repeated surgery for recurrence of disease 3. Persistence of autonomous adrenocortical hormone secretion following surgery. 4. History of prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, or other treated malignancies with no evidence of disease for at least three years 5. Renal insufficiency (creatinine clearance < 40 ml/min). Creatinine clearence may be calculted according to validated formulas (Crockoft’s or MDRD) 6. Liver insufficiency (serum bilirubin > 2 times the upper normal range and/or serum transaminases (AST/SGOT, ALT/SGPT) >3 times the upper normal range). 7. Pregnancy or breast feeding 8. Previous or current treatment with mitotane or other antineoplastic drugs for ACC 9. Previous radiotherapy of the tumour bed for ACC 10. Any other severe acute or chronic medical or psychiatric condition,or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome measure is recurrence free survival (RFS), defined as the time between the date of randomisation until documentation of either of the following events (whichever occurs first): - local or distant recurrence of ACC - death from any cause |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
it is calculated that 97 events in the primary endpoint RFS should be observed and approximately 184 patients should be randomised considering 4 years of accrual and 2 years of follow-up after entry of the last patient. Assuming a lost-to-follow-up rate of maximum 10%, a total of 200 patients (100 per treatment arm) will be needed. The two interim analyses will be carried out at 20% and 60% of the information rate (that under constant accrual rate correspond to about 2 years observation time and 19 expected events and, 4 years observation time and 58 expected events, respectively) Critical p-values for stopping are determined at p = 0.00001 for the first interim analysis, p = 0.01202 for the second and p = 0.0464 for the final analysis. |
|
E.5.2 | Secondary end point(s) |
• Overall Survival, defined as the time interval between the date of randomisation and the date of death from any cause. • Time to recurrence, defined as the time between the date of randomisation and documentation of local or distant recurrence of ACC, or death from ACC (whichever occurs first). • Disease Free Survival, defined as the time interval between the date of randomisation and documentation of any relevant cancer disease, or death of any cause (whichever occurs first). • Quality of life Quality of life will be measured by the standardised EORTC-QLQ-C30 questionnaire. Two measures for the change are dealt with, the change in global quality of life at the time of first evaluation and the average change in global quality of life within the first two years or up to recurrence (whichever occurs first) both in reference to the baseline value. • Toxicity, safety measures that will be used in the study include physical examination and clinical laboratory tests (haematology, blood chemistries and creatinine clearance). Adverse events will be graded using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 • Incidence of second primary cancers. • RFS, TTR, DFS and OS in patients who achieve or not plasma mitotane concentrations >/= 14 mg/L. • RFS TTR, DFS and OS in patient subgroups stratified according to: - Type of hormone secretion (cortisol secreting tumours vs. purely sex- hormone secreting tumours vs. non secreting tumours) - Stage of disease (according to the ENSAT classification 2008) - Histopathological characteristics |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After patients have been under follow-up monitoring for at least 2 years. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Simple observation post surgical excision |
|
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 13 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
For the purposes of the MHRA the end of trial will be 2 months after the last patient has completed protocol treatment . This will allow sufficient time for the completion of protocol procedures, data collection and data input. For the purposes of main REC approval, the trial end date is deemed to be the date of last data capture following 2 years of long-term follow-up. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 9 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |